Endometrial Cancer Diagnosis
Endometrial Cancer Diagnosis
The diagnostic pathway for endometrial cancer is short and mostly outpatient: an ultrasound that measures the lining, a biopsy that makes the diagnosis, an MRI that measures invasion, and a molecular panel that now sits alongside the anatomy in FIGO 2023 staging. Most patients move through all four steps within two to three weeks.
The first tests
When abnormal bleeding brings a woman to the clinic, two tests start the work-up, both outpatient and both usually done the same week:
- Transvaginal ultrasound — measures the thickness of the endometrium and shows fibroids, polyps and the ovaries. After menopause, a thin lining (below roughly 4–5 mm) makes cancer very unlikely; a thickened lining prompts the biopsy. Before menopause, thickness is read against the cycle and the symptom.
- Office endometrial biopsy — a thin sampling device passed through the cervix to take a strip of the lining. It takes minutes, needs no anaesthesia in most cases, and provides the tissue that makes or excludes the diagnosis.
The ultrasound is a filter; the biopsy is the diagnosis. Neither takes the place of the other — a normal-looking ultrasound with persistent bleeding still deserves a biopsy where the history is suggestive, and a thickened lining is far more often hyperplasia or a polyp than cancer.
The biopsy that decides
The pathology report from the biopsy answers four questions at once, and each one shapes what follows:
- Is there cancer, and of what type? — endometrioid, serous, clear cell or carcinosarcoma; the type carries the treatment route with it.
- What grade? — endometrioid tumours are graded G1 to G3 by how much gland-like structure they retain; grade is one of the two pillars of risk assessment.
- What do the molecular markers show? — mismatch-repair and p53 immunohistochemistry, with POLE sequencing where indicated, run on the same tissue and assign the molecular class.
- Is there lymph-vascular space invasion? — tumour cells inside small vessels, a risk feature that nudges the plan toward nodal assessment and adjuvant therapy.
The office sample is small, and in a minority of cases it is insufficient or discordant with the ultrasound — that is what hysteroscopy is for. But when it is adequate, it carries enough information that the staging MRI and even the surgical plan can proceed without waiting for another procedure.
Hysteroscopy and D&C
Hysteroscopy places a fine camera inside the uterine cavity and shows the lining directly: polyps, localised thickening and the patches the blind office biopsy can miss. Directed biopsies under direct vision are taken of anything suspicious, and polyps or a localised lesion can often be removed at the same sitting. Dilation and curettage — a broader scraping of the cavity, done under light anaesthesia — is the alternative where hysteroscopy is not available or the cervix needs gentle dilation.
Hysteroscopy matters most in three situations: the office biopsy came back insufficient; the biopsy showed hyperplasia with atypia and the extent needs mapping before deciding between hysterectomy and progestin therapy; and bleeding persists after a negative first sample. It is also the procedure of choice for women being considered for fertility preservation, where the exact extent of the lesion determines whether the pathway is even open.
MRI and CT
With the diagnosis made, imaging answers the question the biopsy cannot: how far has the tumour gone?
- Pelvic MRI — the definitive test for depth of myometrial invasion and for cervical stroma involvement, both of which separate stage IA from IB and II. It also shows enlarged pelvic nodes and, where fertility preservation is considered, whether the lesion is confined to the lining.
- CT of chest and abdomen — covers the nodal basins above the pelvis and the distant organs; used where risk features or symptoms point beyond the pelvis, and standard before treatment of serous, clear-cell and high-grade disease.
- PET-CT — reserved for selected cases where nodal status remains uncertain and the answer would change the plan.
The practical sequence for most patients: ultrasound and biopsy in the first week, MRI in the second, and the surgical date set once both are read. None of the imaging replaces the biopsy — but without the MRI, the depth of invasion is unknown until the operation, and both the surgical approach and the consent discussion are better made with that number in hand.
FIGO 2023 staging
Endometrial cancer was the first common cancer whose staging system was rewritten to include molecular findings. FIGO 2023 keeps the anatomical spine — uterus, cervix, beyond the uterus, distant — and overlays the four molecular classes on top of it:
- POLE-mutated tumours are reclassified downward — a tumour with high-risk anatomy but a POLE mutation moves to a better-prognosis category, because the biology outweighs the anatomy.
- p53-abnormal tumours are reclassified upward — disease confined to the lining with abnormal p53 is staged as if it were more advanced, because its behaviour follows serous cancer.
- MMR-deficient and NSMP tumours stay anatomically staged, with the class recorded alongside as a modifier of adjuvant decisions.
The effect on patients is concrete: two women with identical-looking disease on MRI can sit in different stages and receive different post-operative treatment, purely on the molecular report. This is why the biopsy — not just the resected uterus — should have been tested, and why records sent for a second opinion should always include the pathology and the molecular panel, not only the imaging. The full stage-by-stage breakdown is on the overview page and in the treatment page.
What we do with your records
The diagnostic pathway depends on records arriving in order, and most delays we see are missing items rather than missing capability. The file that lets our team give a complete answer contains:
- The ultrasound report, with the endometrial measurement
- The biopsy or hysteroscopy pathology report — including grade, type and lymph-vascular space invasion
- The molecular results if done: POLE, mismatch-repair, p53; if not done, the tissue block or slides themselves
- The pelvic MRI on disc or in shared format, with the report
- Any CT already performed, and the operation note if surgery has happened
With those items, our gynaecological oncology MDT returns a written assessment within 48 hours of the file being complete: the likely stage under FIGO 2023, whether the molecular class would change it, the surgical approach implied, and what remains to be confirmed. Where the molecular tests have not been done, we say so explicitly — running them on existing tissue is often the single highest-value step before any treatment decision.